Genomics & Omics Analysis - software & AI news

Daily news on software, AI, and companies shaping genomics & omics analysis.

Showing 241 results
Press release cover image

Oct 26, 2026

Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer

Beta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing1Building on its leadership in colorectal cancer screening with the Cologuard® test, Abbott is connecting innovations across the cancer care continuum, from early detection to post-treatment monitoringABBOTT PARK, Ill., Oct. 23, 2026 /PRNewswire/ -- For patients with colorectal cancer, surgery can remove visible cancer, but it can be difficult to know whethe
Press release cover image

Oct 26, 2026

BostonGene Showcases AI-Powered Multimodal Analytics at ESMO Congress 2025 to Advance Cancer Research and Drug Development

Presentations showcase AI-powered multimodal analytics that unblind tumor biology and accelerate drug developmentWALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI foundational model for cancer and immune system, announced today the acceptance of four abstracts at the ESMO Congress 2025. This premier global oncology meeting brings together clinicians, researchers, patient advocates and industry experts to advance cancer science and care. The Congress showcases the latest br
Press release cover image

Oct 26, 2026

GRAIL to Present New Galleri® Data From More Than 32,000 Participants Across the PATHFINDER 2, SYMPLIFY and REFLECTION Studies at ESMO Congress 2025 and EDCC

First PATHFINDER 2 Results Accepted as a Late-Breaking Presentation at the European Society for Medical Oncology (ESMO) Congress 2025; Results to be Submitted to FDA as Part of the Galleri Premarket Approval Application (PMA) Updated SYMPLIFY and REFLECTION Study Results to be Presented at the Early Detection of Cancer Conference (EDCC) Highlight Galleri Performance in Symptomatic and Veteran Populations, RespectivelyMENLO PARK, Calif., Sept. 23, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL),
A minimalist illustration of a tumor and a drug capsule in flat design.

Oct 23, 2026

Multiomic Study of MSS CRC Identifies Vulnerabilities Pointing to Therapeutic Possibilities

An international research initiative has unveiled potential therapeutic avenues for microsatellite stable (MSS) colorectal cancer (CRC), a subtype known for its treatment resistance. Spearheaded by RCSI University of Medicine and Health Sciences and The Institute of Cancer Research, London, the study integrated extensive multiomic data from approximately 2,000 CRC tumors, utilizing an AI tool named iPhenMap to create detailed biological tumor maps.The findings revealed specific vulnerabilities w
Press release cover image

Oct 22, 2026

Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers

SALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces new data from the ongoing MONSTAR-SCREEN-3 study demonstrating the potential of its whole-genome sequencing (WGS)-based Precise MRD™ platform to support ultra-sensitive molecular residual disease (MRD) detection in patients with resectable colorectal and pancreatic cancers. The findings, which will be presented as part of the
Press release cover image

Oct 22, 2026

Ignite Proteomics Enters Breast Cancer Research Collaboration with Leading Cancer Center

GOLDEN, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ignite Proteomics, Inc. (“Ignite” or the “Company”), a precision oncology company focused on functional proteomics, today announced it is collaborating with Memorial Sloan Kettering Cancer Center (“MSK”) to study protein signaling patterns associated with treatment response and resistance in advanced breast cancer. Ignite will apply its reverse phase protein array (“RPPA”)-based proteomic test to tumor samples. The effort will evaluate proteomic
Minimalist illustration of a pancreas and tumor microenvironment

Oct 21, 2026

Bridging the Translational Gap in Pancreatic Cancer Through Biology-First Modeling

Innovative approaches are reshaping pancreatic cancer research by enhancing the connection between patient biology and preclinical models.Recent advancements in pancreatic cancer therapies highlight the need for improved translational pipelines that effectively link patient biology to preclinical systems. The tumor microenvironment plays a pivotal role in determining patient outcomes and therapeutic responses, necessitating its accurate representation in research models.In an upcoming webinar, J
Press release cover image

Oct 21, 2026

Mapmygenome Completes Acquisition of dnaPower Inc. to Accelerate North American Expansion in DNA, Microbiome, Longevity and Precision Health Testing

VANCOUVER, BC, Oct. 21, 2026 /PRNewswire/ -- Mapmygenome announced the completion of its acquisition of Vancouver-based dnaPower Inc., a pioneer in personal genomics. The strategic transaction expands Mapmygenome's North American footprint and establishes a market-leading platform in DNA testing, gut microbiome health, longevity, and AI-driven multi-omics testing.Continue Reading By uniting dnaPower with Mapmygenome's global scale and premier CAP-accredited clinical laboratory c
Press release cover image

Oct 21, 2026

Therna Biosciences Showcases RNA-Logix™, Its AI RNA Biologist Platform for Biological Discovery and Genomic Medicine Design

RNA-Logix connects biological questions, experimental evidence, and RNA medicine design in a single investigative workflowThe platform integrates NVIDIA accelerated computing and BioReason-RNA, a model developed in collaboration with NVIDIA that predicts RNA function and proposes the mechanisms behind itSAN FRANCISCO--(BUSINESS WIRE)--Therna Biosciences, a biotechnology company translating RNA language into genomic medicines, today showcased RNA-Logix™, its Recursive AI RNA Biologist platform. R
Press release cover image

Oct 21, 2026

Illumina BioInsight Platform expands with new software to accelerate the path from sequencing to discovery

DRAGEN Ultra, BioInsight Platform Workflow Orchestrator, and BioInsight Platform Learning Cohorts are now available in early access, incorporating new AI-driven approaches to analysis, automation, and discoveryThe tools automate end-to-end informatics processes at scale and help customers build private data lakes to drive scientific and clinical research insightsSAN DIEGO, Oct. 21, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today introduced three early-access capabilities on its BioInsig
Press release cover image

Oct 21, 2026

New York Labor Health Care Alliance Endorses Blue Genes Lab to Stop Unsafe and Ineffective Drugs Before They're Filled for 79 Unions and 150,000 Members and Dependents

Unlike traditional pharmacogenetics programs that just send a report, Blue Genes acts in real time inside the claims flow, protecting workers and holding down plan costsALBANY, N.Y. and PHOENIX, Oct. 21, 2026 /PRNewswire/ -- Blue Genes Lab, a leading pharmacogenetics (PGx) provider with a groundbreaking approach to using genetic data to protect patients and reduce costs for payers at the moment it matters, today announced that it has been endorsed by the New York Labor Health Care Alliance (NYLH
Press release cover image

Oct 21, 2026

Syntax Bio Programs Stem Cells Toward Pancreatic Beta Cells in Four Days

New Cellgorithm™ data presented at ISSCR symposium indicates faster, scalable cell programming and add to Syntax Bio’s compounding proprietary dataCompany completes pancreatic beta cell screening milestones for lead program and enters process development with continued funding from Breakthrough T1DCHICAGO--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming next generation regenerative medicines, today presented new research showing that its Cellgorithm™ platform differentiated